4563 AnGes,Inc.アンジェスTSE Growth / Pharmaceuticals
0 posts
AnGes,Inc. (4563) at a glance
Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.
AnGes,Inc. (4563) Stock Price HistoryNear an all-time low
AnGes,Inc. closed at ¥24.0 on Nov 20, 2026, −17.2% over 1 month, −68.0% over 1 year.
If you had invested ¥100,000 1 month ago, it would be worth ¥82,759 today (−17.2%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −11.9%, while this stock moved −17.2%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥24.0 | −1 | −4.00% |
| Nov 19 (Thu) | ¥25.0 | +0 | +0.00% |
| Nov 18 (Wed) | ¥25.0 | +1 | +4.17% |
| Nov 17 (Tue) | ¥24.0 | −1 | −4.00% |
| Nov 16 (Mon) | ¥25.0 | −2 | −7.41% |
| Nov 13 (Fri) | ¥27.0 | +1 | +3.85% |
| Nov 12 (Thu) | ¥26.0 | −1 | −3.70% |
| Nov 11 (Wed) | ¥27.0 | +1 | +3.85% |
| Nov 10 (Tue) | ¥26.0 | −1 | −3.70% |
| Nov 9 (Mon) | ¥27.0 | +2 | +8.00% |
If you had invested ¥100,000 3 months ago, it would be worth ¥57,143 today (−42.9%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −14.8%, while this stock moved −42.9%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥24.0 | −1 | −4.00% |
| Nov 19 (Thu) | ¥25.0 | +0 | +0.00% |
| Nov 18 (Wed) | ¥25.0 | +1 | +4.17% |
| Nov 17 (Tue) | ¥24.0 | −1 | −4.00% |
| Nov 16 (Mon) | ¥25.0 | −2 | −7.41% |
| Nov 13 (Fri) | ¥27.0 | +1 | +3.85% |
| Nov 12 (Thu) | ¥26.0 | −1 | −3.70% |
| Nov 11 (Wed) | ¥27.0 | +1 | +3.85% |
| Nov 10 (Tue) | ¥26.0 | −1 | −3.70% |
| Nov 9 (Mon) | ¥27.0 | +2 | +8.00% |
If you had invested ¥100,000 6 months ago, it would be worth ¥48,980 today (−51.0%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −5.6%, while this stock moved −51.0%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥24.0 | −17.2% |
| Oct 2026 | ¥29.0 | −23.7% |
| Sep 2026 | ¥38.0 | −2.6% |
| Aug 2026 | ¥39.0 | −17.0% |
| Jul 2026 | ¥47.0 | +0.0% |
| Jun 2026 | ¥47.0 | −4.1% |
| May 2026 | ¥49.0 | −5.8% |
If you had invested ¥100,000 1 year ago, it would be worth ¥32,000 today (−68.0%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +13.3%, while this stock moved −68.0%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥24.0 | −17.2% |
| Oct 2026 | ¥29.0 | −23.7% |
| Sep 2026 | ¥38.0 | −2.6% |
| Aug 2026 | ¥39.0 | −17.0% |
| Jul 2026 | ¥47.0 | +0.0% |
| Jun 2026 | ¥47.0 | −4.1% |
| May 2026 | ¥49.0 | −5.8% |
| Apr 2026 | ¥52.0 | −8.8% |
| Mar 2026 | ¥57.0 | −3.4% |
| Feb 2026 | ¥59.0 | −1.7% |
| Jan 2026 | ¥60.0 | −1.6% |
| Dec 2025 | ¥61.0 | −17.6% |
| Nov 2025 | ¥74.0 | ― |
If you had invested ¥100,000 3 years ago, it would be worth ¥28,235 today (−71.8%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +67.8%, while this stock moved −71.8%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥24.0 | −60.7% |
| 2025 | ¥61.0 | ― |
If you had invested ¥100,000 5 years ago, it would be worth ¥5,660 today (−94.3%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +96.3%, while this stock moved −94.3%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥24.0 | −60.7% |
| 2025 | ¥61.0 | ― |
If you had invested ¥100,000 in Oct 2002, it would be worth ¥1,345 today (−98.7%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +557.9%, while this stock moved −98.7%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥24.0 | −60.7% |
| 2025 | ¥61.0 | +15.1% |
| 2024 | ¥53.0 | −26.4% |
| 2023 | ¥72.0 | −41.0% |
| 2022 | ¥122 | −68.2% |
| 2021 | ¥384 | −69.2% |
| 2020 | ¥1,245 | +94.8% |
| 2019 | ¥639 | +76.0% |
| 2018 | ¥363 | −41.4% |
| 2017 | ¥619 | +147.6% |
| 2016 | ¥250 | +8.7% |
| 2015 | ¥230 | −37.8% |
| 2014 | ¥370 | −29.3% |
| 2013 | ¥523 | +130.7% |
| 2012 | ¥227 | +20.8% |
| 2011 | ¥188 | −61.4% |
| 2010 | ¥487 | −18.5% |
| 2009 | ¥598 | +5.7% |
| 2008 | ¥566 | −78.5% |
| 2007 | ¥2,628 | +1.8% |
| 2006 | ¥2,582 | −27.0% |
| 2005 | ¥3,535 | +57.7% |
| 2004 | ¥2,243 | −35.3% |
| 2003 | ¥3,468 | +79.8% |
| 2002 | ¥1,929 | ― |
Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Oct 2002). Please check the latest prices before trading.
AnGes,Inc. (4563) financial indicators
PER, ROE and dividend yield are based on company forecasts, calculated from earnings reports and the closing price after each trading day.
Key features of AnGes,Inc. (4563)
Business overview
Together with three consolidated subsidiaries, the company develops and sells pharmaceuticals centered on gene-based medicines, and also provides contract testing services centered on screening for rare genetic diseases. The company handles R&D and sales of gene therapy products, nucleic acid drugs and more and contract testing, and its US subsidiary AnGes USA, Inc. handles drug development in the United States. Subsidiary EmendoBio Inc. is advancing R&D in the United States of genome editing products that could treat diseases with no previous treatment, with research and development carried out by a subsidiary in Israel. Since the probability of bringing a new drug to market from a candidate compound is said to be about 1 in 30,000 and development often takes more than 10 years, its business structure has R&D costs coming first. In April 2021 it opened a testing facility and takes on screening tests for rare genetic diseases from local governments and medical institutions.
Summarized from the annual securities report (fiscal year ended December 2025) filed on EDINET.
Position within Pharmaceuticals (79 companies)
| PBR | 75.97x | Above the sector median of 1.86x (No. 76 from the lowest) |
|---|---|---|
| ROE | -8,157.13% | No. 54 in the sector (highest first); median 4.17% |
| Market cap | ¥9.6 bn | No. 46 in the sector (largest first) |
Ranks among stocks in the same Tokyo Stock Exchange sector (33 sectors). PER and PBR of zero or below (losses, negative equity) are excluded and ranked from the lowest.
Price milestones
| 52-week high | ¥75 | 2025/11/20 |
|---|---|---|
| 52-week low | ¥24 | 11/20 |
| Current position | 0.0% | Where the low is 0% and the high is 100% (close on 11/20: ¥24) |
| Year to date | -60.7% | No. 75 of 77 in the sector (best first) |
| 1 year | -68.0% |
Based on closing prices (adjusted for stock splits, excluding dividends).
Kabutaro's ranking history
| Top 50 losers | 3 times | Latest: 11/10 (No. 46) |
|---|
Gainers and losers have been recorded since 9/2026.
Calculated as of 2026/11/20 17:30 JST. Updated every business day in the evening.
Recent disclosures (TDnet, in Japanese)
- 11/13 16:00営業外収益、営業外費用、特別利益、特別損失並びに法人税等調整額の計上及び業績予想の修正に関するお知らせ
- 11/13 16:002026年12月期第3四半期決算短信〔日本基準〕(連結)
- 11/02 16:00行使価額修正条項付新株予約権の月間行使状況に関するお知らせ
- 10/06 08:45共同開発品Tie2受容体アゴニスト(AV-001)の皮下注製剤の開発推進に向けた助成金獲得のお知らせ
- 10/01 16:00行使価額修正条項付新株予約権の月間行使状況に関するお知らせ
- 09/29 08:45共同開発品Tie2受容体アゴニスト(AV-001)の前期第2相臨床試験登録完了のお知らせ
- 09/28 16:00グロースパートナーズとの事業提携による企業価値向上への取り組みについて
- 09/15 16:00第46回新株予約権(行使価額修正条項付)の取得及び消却の完了に関するお知らせ
Filings from the past 12 months (8).
Posts
This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.
No posts yet. Be the first to write something.
Write on the AnGes,Inc. board
More Japanese stocks in English
- OncoTherapy Science,Inc.4564
- Nxera Pharma Co.,Ltd.4565
- KYORIN Pharmaceutical Co.,Ltd.4569
- HUMAN MADE Inc.456A
- Immuno-Biological Laboratories Co.,Ltd.4570
- Nano Holdings,Inc.4571
- Carna Biosciences,Inc.4572
- TAIKO PHARMACEUTICAL CO.,LTD.4574
- CanBas Co.,Ltd.4575
- D.Western Therapeutics Institute, Inc.4576
- Daito Pharmaceutical Co.,Ltd.4577
- RaQualia Pharma Inc.4579